Berenberg Bank analyst Dev Weerasuriya reiterated a Buy rating on Progyny (PGNY – Research Report) today and set a price target of $58.00. The company’s shares closed last Thursday at $29.77, close to its 52-week low of $25.67.
According to TipRanks.com, Weerasuriya is a 3-star analyst with an average return of 4.6% and a 47.4% success rate. Weerasuriya covers the Technology sector, focusing on stocks such as Health Catalyst, Omnicell, and Accolade.
Currently, the analyst consensus on Progyny is a Strong Buy with an average price target of $52.50, implying a 61.8% upside from current levels. In a report issued on July 21, Bank of America Securities also maintained a Buy rating on the stock with a $48.00 price target.
Progyny’s market cap is currently $2.74B and has a P/E ratio of 53.64.
Based on the recent corporate insider activity of 122 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PGNY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Progyny, Inc. is a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools. Its services include egg freezing, IVF treatment, surrogacy, podcast, adoption, and Eeva Test. The company was founded on April 03, 2008 and is headquartered in New York, NY.
Read More on PGNY: